+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030- Product Image
Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030- Product Image
New

Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • PDF Icon

    Report

  • 187 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5941569
Free Webex Call
10% Free customization
Description Jump to:

T-cell Lymphoma is the fastest growing segment, North America is the largest market globally

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Non-Hodgkin Lymphoma Market, valued at USD 7.24 Billion in 2024, is projected to experience a CAGR of 7.72% to reach USD 11.31 Billion by 2030. The global Non-Hodgkin Lymphoma market comprises a comprehensive array of diagnostic tools and therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies such as CAR T-cell therapy, radiation, and stem cell transplantation, tailored for various lymphoma subtypes. Market growth is primarily driven by the increasing global incidence of Non-Hodgkin Lymphoma and a rising preference for advanced treatment modalities like targeted therapies and immunotherapies.

Key Market Drivers

The Global Non-Hodgkin Lymphoma market is significantly propelled by sustained advancements in targeted therapies and immunotherapies, which offer enhanced treatment efficacy and improved patient outcomes. The continuous development of novel agents specifically designed to target molecular pathways implicated in lymphoma pathogenesis has expanded therapeutic options, particularly for patients with relapsed or refractory disease. For instance, according to Genmab, on June 26, 2024, the FDA approved epcoritamab-bysp, known as EPKINLY®, for relapsed or refractory follicular lymphoma, representing the first and only T-cell engaging bispecific antibody administered subcutaneously for this indication. This progress not only provides new lifelines for patients but also fuels market expansion through the introduction of premium-priced, innovative treatments.

Key Market Challenges

The substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments, presents a significant impediment to the growth of the global Non-Hodgkin Lymphoma market. These high expenditures directly limit patient access to potentially life-saving interventions, especially in healthcare systems with constrained budgets or in regions lacking robust insurance frameworks.

Key Market Trends

The non-Hodgkin lymphoma market is significantly influenced by the accelerating shift towards personalized medicine, primarily propelled by advanced genomic profiling. This trend emphasizes tailoring treatments based on an individual patient's unique genetic makeup, leading to more targeted and effective therapeutic interventions. For instance, the European Hematology Association's (EHA) guidelines for large B-cell lymphomas and peripheral T-cell lymphomas in 2025 highlight the increasing cruciality of molecular profiling for accurate diagnosis and subtype identification, which directly informs personalized treatment strategies. The expedited delivery of such critical diagnostic information is further advanced, as exemplified by the FDA approval of Thermo Fisher Scientific's Oncomine Dx Express Test in September 2025, designed for companion diagnostics and tumor profiling with results available in as little as 24 hours. This capability enables faster and more precise treatment decisions, enhancing patient outcomes and driving market expansion for advanced diagnostic solutions.

Key Market Players Profiled:

  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Seagen, Inc (Pfizer Inc.)
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Merck & Co. Inc

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma Market has been segmented into the following categories:

By Disease Type:

  • B-cell Lymphomas
  • T-cell Lymphoma

By Drug Class:

  • Monoclonal Antibodies
  • Antibody-Drug Conjugates
  • BTK/BCL-2 Kinase Inhibitors
  • PI3 Kinase Inhibitors
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Hodgkin Lymphoma Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:
  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-Hodgkin Lymphoma Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (B-cell Lymphomas, T-cell Lymphoma)
5.2.2. By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Others)
5.2.3. By Route of Administration (Oral, Parenteral, Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Non-Hodgkin Lymphoma Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Drug Class
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Hodgkin Lymphoma Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Drug Class
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Non-Hodgkin Lymphoma Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Drug Class
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Non-Hodgkin Lymphoma Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Drug Class
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
7. Europe Non-Hodgkin Lymphoma Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Drug Class
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Hodgkin Lymphoma Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Drug Class
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. France Non-Hodgkin Lymphoma Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Drug Class
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Non-Hodgkin Lymphoma Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Drug Class
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Non-Hodgkin Lymphoma Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Drug Class
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Non-Hodgkin Lymphoma Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Drug Class
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Non-Hodgkin Lymphoma Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Drug Class
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Hodgkin Lymphoma Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Drug Class
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. India Non-Hodgkin Lymphoma Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Drug Class
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Non-Hodgkin Lymphoma Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Drug Class
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Non-Hodgkin Lymphoma Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Drug Class
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Non-Hodgkin Lymphoma Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Drug Class
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Non-Hodgkin Lymphoma Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Hodgkin Lymphoma Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Drug Class
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Non-Hodgkin Lymphoma Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Drug Class
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Non-Hodgkin Lymphoma Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Drug Class
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
10. South America Non-Hodgkin Lymphoma Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Hodgkin Lymphoma Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Drug Class
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Non-Hodgkin Lymphoma Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Drug Class
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Non-Hodgkin Lymphoma Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Drug Class
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Non-Hodgkin Lymphoma Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. AbbVie Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bristol-Myers Squibb Company
15.3. AstraZeneca plc
15.4. Johnson & Johnson Services, Inc.
15.5. Novartis AG
15.6. Seagen, Inc (Pfizer Inc.)
15.7. Bayer AG
15.8. F. Hoffmann-La Roche Ltd
15.9. Gilead Sciences Inc
15.10. Merck & Co. Inc
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Seagen, Inc (Pfizer Inc.)
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Merck & Co. Inc

Table Information

Report AttributeDetails
No. of Pages187
PublishedNovember 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.31 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025 - Product Image

B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report 2025 - Product Image

B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Non Hodgkin Lymphoma (NHL) Market Report 2025 - Product Image

Non Hodgkin Lymphoma (NHL) Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Non-Hodgkin Lymphoma - Pipeline Insight, 2025 - Product Image

Non-Hodgkin Lymphoma - Pipeline Insight, 2025

  • Clinical Trials
  • 450 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.